•
Jun 30, 2023

Zimmer Biomet Q2 2023 Earnings Report

Reported a strong second quarter with sales and earnings growth, raised full-year financial guidance.

Key Takeaways

Zimmer Biomet announced its second quarter 2023 financial results, reporting net sales of $1.870 billion, a 4.9% increase over the prior year, and a 6.0% increase on a constant currency basis. Net earnings were $209.6 million, with diluted earnings per share at $1.00. The company has raised its 2023 financial guidance based on its business performance and innovation pipeline.

Second quarter net sales increased 4.9% to $1.870 billion, and 6.0% on a constant currency basis.

Second quarter diluted earnings per share were $1.00; adjusted diluted earnings per share were $1.82.

The company received U.S. FDA 510k clearance for ActivBraidâ„¢.

Zimmer Biomet was certified in multiple countries by Great Place to Work®.

Total Revenue
$1.87B
Previous year: $1.78B
+4.9%
EPS
$1.82
Previous year: $1.82
+0.0%
Gross Profit
$1.34B
Previous year: $1.27B
+5.8%
Cash and Equivalents
$320M
Previous year: $386M
-17.2%
Free Cash Flow
$251M
Total Assets
$21.3B
Previous year: $21.5B
-0.7%

Zimmer Biomet

Zimmer Biomet

Zimmer Biomet Revenue by Segment

Forward Guidance

The Company is providing the following updated full-year 2023 financial guidance:

Positive Outlook

  • 2023 Reported Revenue Change: 6.5% - 7.0%
  • Foreign Currency Exchange Impact: (0.5)%
  • Adjusted Diluted EPS: $7.47 - $7.57

Revenue & Expenses

Visualization of income flow from segment revenue to net income